In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Daniel García-ArceDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0009-0008-2893-1911 Myrna Luna-GutiérrezDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-4082-3816 Pedro Cruz-NovaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
Abraham Vidal-LimonRed de Estudios Moleculares Avanzados, Instituto de Ecología A.C. (INECOL), El Haya, Xalapa 91073, Mexico.ORCID 0000-0001-5674-7881 Nallely Jiménez-MancillaIxM SECIHTI-ININ, Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-9480-4621 Liliana Aranda-LaraFaculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.ORCID 0000-0003-4066-2327 Erika Azorín-VegaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-7520-461X Enrique Morales-AvilaFaculty of Chemistry, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.ORCID 0000-0001-8471-6791 Paola Rodríguez-LópezDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
Clara Santos-CuevasDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-5903-1598 Guillermina Ferro-FloresDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0003-0296-7605 Blanca Ocampo-GarcíaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-5831-8412 Funding
International Atomic Energy Agency CRP-F22075Secretaría de Ciencia, Humanidades, Tecnología e Innovación CBF-2025-I-2979
6 · The paper itselfAbstract
Prostate-specific membrane antigen (PSMA) is a validated theranostic target with clinical relevance extending beyond prostate cancer to PSMA-expressing neovasculature in solid tumors. Despite the success of
Indexed as
ActiniumAlpha ParticlesGlutamate Carboxypeptidase IIProstatic NeoplasmsRadiopharmaceuticalsAnimalsAntigens, SurfaceCell Line, TumorDrug DesignHumansMaleMiceTissue DistributionActiniumActinium-225Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticalsActinium-225combination therapydimeric radiopharmaceuticalDOTAHYNIC-iPSMAMACROPAmonomericPSMAtargeted alpha therapy
Identifiers
PMID42737682
PMCPMC13565901
What Socratic holds
Textmetadata
Read underepoch 390